厦门飞朔生物技术有限公司 is a leading company in Xiamen, China, specializing in the development, sales, and services of innovative solutions for personalized precision medicine testing, focusing on tumor individualized testing. Their services include early screening, disease diagnosis, personalized drug selection, and treatment monitoring. The company possesses a 3500m² international standard GMP workshop and a 2000m² research and quality control laboratory.

With a strong research and technical team, they have advanced platforms such as high-throughput sequencing, digital PCR, fluorescent quantitative PCR, nucleic acid mass spectrometry, and more. To date, they have independently developed over 40 products, obtained 35 domestic patents, 3 international PCT patents, 6 invention patents, 2 utility model patents, and 12 software copyright authorizations. They have also achieved ISO13485 medical device quality management system certification and multiple CE-IVD certifications.

Committed to promoting public health, the company aims to be an international leading specialized molecular diagnostic company and continues to prioritize quality, reputation, management, and service to contribute to society and benefit patients